Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.

Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.

<h4>Purpose</h4>Radiolabeled Prostate-Specific Membrane Antigen (PSMA) PET/CT is the current standard-of-care for lesion detection in patients with biochemically recurrent (BCR) prostate cancer (PCa). However, rigorous verification of detected lesions is not always performed in routine c...

Full description

Bibliographic Details
Main Authors: Dennie Meijer, Bernard H E Jansen, Maurits Wondergem, Yves J L Bodar, Sandra Srbljin, Annelies E Vellekoop, Bram Keizer, Friso M van der Zant, Otto S Hoekstra, Jakko A Nieuwenhuijzen, Max Dahele, André N Vis, Daniela E Oprea-Lager
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0239414

Internet

https://doi.org/10.1371/journal.pone.0239414

Similar Items